» Authors » Martina Chiacchiaretta

Martina Chiacchiaretta

Explore the profile of Martina Chiacchiaretta including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 194
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Braga A, Chiacchiaretta M, Pellerin L, Kong D, Haydon P
Nat Commun . 2024 Jul; 15(1):5979. PMID: 39013907
Neuronal activity undergoes significant changes during vigilance states, accompanied by an accommodation of energy demands. While the astrocyte-neuron lactate shuttle has shown that lactate is the primary energy substrate for...
2.
Centonze E, Marte A, Albini M, Rocchi A, Cesca F, Chiacchiaretta M, et al.
J Neurochem . 2023 Jan; 165(5):701-721. PMID: 36636908
Neuron-restrictive silencer factor/repressor element 1 (RE1)-silencing transcription factor (NRSF/REST) is a transcriptional repressor of a large cluster of neural genes containing RE1 motifs in their promoter region. NRSF/REST is ubiquitously...
3.
Moschetta M, Chiacchiaretta M, Cesca F, Roy I, Athanassiou A, Benfenati F, et al.
Front Neurosci . 2021 Oct; 15:731198. PMID: 34616276
The use of composite biomaterials as innovative bio-friendly neuronal interfaces has been poorly developed so far. Smart strategies to target neuro-pathologies are currently exploiting the mixed and complementary characteristics of...
4.
Scaramuzza L, De Rocco G, Desiato G, Cobolli Gigli C, Chiacchiaretta M, Mirabella F, et al.
EMBO Mol Med . 2021 Mar; 13(4):e12433. PMID: 33665914
MECP2 mutations cause Rett syndrome (RTT), a severe and progressive neurodevelopmental disorder mainly affecting females. Although RTT patients exhibit delayed onset of symptoms, several evidences demonstrate that MeCP2 deficiency alters...
5.
Lombardo S, Chiacchiaretta M, Tarr A, Kim W, Cao T, Sigal G, et al.
Sci Rep . 2019 Dec; 9(1):19877. PMID: 31882662
BACE1 is the first enzyme involved in APP processing, thus it is a strong therapeutic target candidate for Alzheimer's disease. The observation of deleterious phenotypes in BACE1 Knock-out (KO) mouse...
6.
Castelli M, Piobbico D, Chiacchiaretta M, Brunacci C, Pieroni S, Bartoli D, et al.
EMBO Rep . 2019 Dec; 21(2):e48073. PMID: 31867855
Apoptotic signalling by p53 occurs at both transcriptional and non-transcriptional levels, as p53 may act as a direct apoptogenic stimulus via activation of the intrinsic mitochondrial pathway. HOPS is a...
7.
Jaudon F, Chiacchiaretta M, Albini M, Ferroni S, Benfenati F, Cesca F
Cell Death Differ . 2019 Oct; 27(5):1505-1519. PMID: 31624352
Through their ability to modulate synaptic transmission, glial cells are key regulators of neuronal circuit formation and activity. Kidins220/ARMS (kinase-D interacting substrate of 220 kDa/ankyrin repeat-rich membrane spanning) is one...
8.
Bramini M, Chiacchiaretta M, Armirotti A, Rocchi A, Kale D, Martin C, et al.
Small . 2019 Mar; 15(15):e1900147. PMID: 30891923
The use of graphene nanomaterials (GNMs) for biomedical applications targeted to the central nervous system is exponentially increasing, although precise information on their effects on brain cells is lacking. In...
9.
Chiacchiaretta M, Bramini M, Rocchi A, Armirotti A, Giordano E, Vazquez E, et al.
Nano Lett . 2018 Aug; 18(9):5827-5838. PMID: 30088941
Graphene-based materials are the focus of intense research efforts to devise novel theranostic strategies for targeting the central nervous system. In this work, we have investigated the consequences of long-term...
10.
Bramini M, Alberini G, Colombo E, Chiacchiaretta M, DiFrancesco M, Maya-Vetencourt J, et al.
Front Syst Neurosci . 2018 Apr; 12:12. PMID: 29695956
The scientific community has witnessed an exponential increase in the applications of graphene and graphene-based materials in a wide range of fields, from engineering to electronics to biotechnologies and biomedical...